Navigation Links
Kosan Announces Third Quarter 2007 Financial Results
Date:11/8/2007

President and Chief Executive Officer. "We believe that the growing body of positive clinical data that we have generated in our clinical trials to date, combined with development and regulatory strategies that are being successfully implemented in all of our clinical programs and the commercial potential of our Hsp90 and epothilone programs, position Kosan as an attractive investment opportunity."

Third Quarter 2007 Highlights

-- Kosan reached a binding agreement with the U.S. Food and Drug

Administration (FDA) on the design of Kosan's TIME-1 clinical trial, a

pivotal Phase 3 trial of Kosan's Hsp90 inhibitor tanespimycin as a

treatment for patients with multiple myeloma, through a Special

Protocol Assessment (SPA) process with the FDA. Kosan also completed

the "Scientific Advice" process with the centralized European Medicines

Agency (EMEA) for TIME-1.

-- At the 2007 Breast Cancer Symposium of the American Society of Clinical

Oncology (ASCO), Kosan presented updated data from a Phase 1 clinical

trial showing that Kosan's Hsp90 inhibitor alvespimycin demonstrated

antitumor activity and tolerability in combination with trastuzumab

(Herceptin(R)), with clinical benefit observed in 42% of evaluable

patients (8 of 19 evaluable) with HER2-positive metastatic breast

cancer.

-- Pfizer Inc. initiated a Phase 1 clinical trial designed to test the

safety, tolerability and pharmacokinetics of motilin receptor agonist

KOS-2187, a selective and potent motilin receptor agonist being

developed for the treatment of gastroesophageal reflux disease (GERD)

and potentially other gastrointestinal disorders.

-- Kosan completed preparations and is planning to initiate later this

quarter a Phase 2 clinical trial of alvespimycin in patients with

newly-diagnosed HER2-positive metastatic breast cance
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
3. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
4. Kosan Biosciences to Host Research & Development Day on October 31, 2007
5. Kosan to Reacquire Epothilone Program From Roche
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
(Date:9/18/2014)... 18, 2014 HealthTronics, Inc ... interventional radiology products and services, announced that a ... and cryoablation) versus external beam radiotherapy (EBRT) is ... American Urological Association (MAAUA) Annual Meeting in Baltimore, ... Effectiveness of Cryosurgery and External Beam Radiation as ...
(Date:9/18/2014)... September 18, 2014 A novel robotic ... MRI scanner is currently being tested as part of ... Hospital in Boston with the aim of determining if ... make prostate cancer biopsies faster, more accurate, less costly, ... also has the potential to deliver prostate cancer therapies ...
(Date:9/18/2014)... 18, 2014 Texas Governor Rick ... Texas A&M Health Science Center CEO Brett Giroir, ... Health and Human Services (HHS), State of Texas ... pandemic influenza vaccine manufacturing facility in Bryan, Texas, ... for the Texas A&M Biocorridor – a rapidly ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... 19 New long-term data from two pivotal, Phase ... arthritis (RA) receiving SIMPONI (TM) (golimumab) every four ... physical function response through one year. These new ... of Rheumatology (ACR) Annual Scientific Meeting. , "New data ...
... , QUEBEC CITY, Oct. 19 /PRNewswire-FirstCall/ - AEterna ... (the "Company"), a global biopharmaceutical company focused on ... has initiated activities intended to complete the clinical ... ghrelin agonist compound macimorelin (AEZS-130) which could be ...
... Holdings, Inc. ("Cellu Tissue") today announced that it has filed a ... Commission (the "SEC") relating to a proposed initial public offering of ... shares to be sold by Cellu Tissue and shares to be ... shares to be offered, the allocation of shares to be sold ...
Cached Biology Technology:New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 2New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 3New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 4New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 5New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 6New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 7New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 8New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 9New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis 10AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 3Cellu Tissue Holdings, Inc. Files Registration Statement for Proposed Initial Public Offering of Common Stock 2
(Date:9/18/2014)... to be cheerful, happy-go-lucky characters, so you might expect ... , In fact some dogs are distinctly more ... shows. , "This research is exciting because it ... and non-invasively. It offers researchers and dog owners an ... changes," said Dr Melissa Starling, from the Faculty of ...
(Date:9/18/2014)... are too stressed they are often grouchy, grumpy, nasty, ... (BMI) at EPFL have just highlighted a fundamental synaptic ... the loss of social skills and cognitive impairment. When ... molecule in the brain. This was revealed by a ... Carmen Sandi,s team went to look for answers in ...
(Date:9/17/2014)... reproductive technologies, the justice and well-being of our ... identify key issues, articulate their values and concerns, ... defensible ways forward. But what are the best ... Hastings Center and the Presidential Commission for the ... publish a series of essays to highlight the ...
Breaking Biology News(10 mins):Dogs can be pessimists too 2Dogs can be pessimists too 3How stress tears us apart 2Why bioethics literacy matters 2Why bioethics literacy matters 3
... The International Institute for Species Exploration at Arizona State ... responsible for species exploration and classification today announce ... On the list are a pea-sized seahorse, caffeine-free coffee ... new species also include the very tiny (a snake ...
... decimated shellfish populations in many of the world,s ... by Whitman Miller, ecologist at the Smithsonian Environmental ... serious threat to these valuable filter feedersrising levels ... acidification of open ocean, coastal and estuarine waters. ...
... in Texas, more than two million homes were without ... others looking for ways to entertain children, a move ... at The University of Texas Health Science Center at ... carbon monoxide poisoning caused by gasoline-powered electrical generators were ...
Cached Biology News:Scientists announce top 10 new species, issue SOS 2Scientists announce top 10 new species, issue SOS 3Scientists announce top 10 new species, issue SOS 4Scientists announce top 10 new species, issue SOS 5Shellfish face an uncertain future in a high CO2 world 2Shellfish face an uncertain future in a high CO2 world 3Pediatric carbon monoxide poisoning linked to video games after Hurricane Ike 2
... BioLogic LP system, 220-240 V, is ... fraction collection. The system includes the ... kit with MV-6 injection valve, proportioning ... cell, tubing and fittings kit, column ...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
Freeze 'N Squeeze DNA gel extraction spin columns use a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. Supplied as 25 columns....
Biology Products: